Login / Signup

G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients.

Sara AvalosRosa E MejiaEngels BanegasCesar SalinasLester GutierrezMarcela FajardoSuzeth GaloAlejandra PintoAngel MejiaGustavo Adolfo Fontecha Sandoval
Published in: Malaria journal (2018)
The findings support that the intake of PQ during 14 days of treatment against vivax malaria is safe in patients with a class III variant of G6PDd. In view of the new national regulations in the shortened treatment of vivax malaria for 7 days, it is advisable to be alert of potential cases of severe haemolysis that could occur among G6PD deficient hemizygous males with a class II mutation such as the Santamaria variant, previously reported in the country.
Keyphrases
  • plasmodium falciparum
  • early onset
  • combination therapy
  • risk assessment
  • climate change
  • quality improvement
  • drug induced